Podcasts about Early Stage

About M2 THE ROCK - MICHAEL MOLTHAN:I'm Michael Molthan, host of The M2 The Rock Show—one of the fastest-growing podcasts and shows on self-improvement, mental health, addiction recovery, and spiritual transformation. I'm so grateful you're here.I started M2 The Rock in 2017 to bring you conversations designed to make you happier, healthier, and more healed. Through raw and unfiltered discussions with experts, celebrities, thought leaders, and athletes, we uncover new perspectives on personal growth, recovery, and overcoming life's toughest challenges.My Story:What sets my journey apart is that there wasn't just one rock bottom—there were many. From being a successful luxury homebuilder to falling into addiction, homelessness, crime, and eventually 27 mugshots and prison, my life was in absolute chaos.Addiction was my temporary escape from childhood trauma, but it only led to destruction.It wasn't until I hit the lowest point imaginable that I finally found true freedom, redemption, and purpose. After an unexpected early release from prison in 2017, I walked 300 miles back to Dallas to turn myself in—only to be miraculously pardoned and told to “pay it forward.”And that's exactly what I've been doing ever since.My MissionI believe that rock bottom is not the end—it's a stepping stone to something greater.My goal is to redefine what "rock bottom" means by helping others rebuild their Spirit, Mind, and Body. On M2 The Rock, I speak openly about trauma, addiction, recovery, and the power of transformation. I don't shy away from topics like:✅ Trauma & Addiction – Understanding the root causes✅ Self-Sabotage & Mental Health – Breaking negative cycles✅ Codependency & Enabling – How relationships impact recovery✅ 12-Step Programs & Spiritual Healing – Finding true freedom✅ Religious Trauma & Personal Growth – Healing from past wounds"Everyone Is An Addict."Whether it's substances, work, validation, or negative thinking, we all have something we struggle with.But recovery is possible, and transformation is real.

Send us a textToday, I have Jason and Tina Marie Scott, certified life and relationship coaches, co-hosts of the Loving Beyond The I Do podcast, and authors of the bestselling book Manifest A Joy-Filled Relationship. With over 33 years of marriage and extensive experience in guiding couples and singles toward fulfilling, long-lasting relationships, they specialize in helping people develop emotional awareness, establish healthy communication, and create genuine, joyful connections. Today, they are here to speak on how to find authentic love and clarity in the dating world, and we'll break this down into three different subcategoriesDating with Intention: How to Attract the Right Relationship – Tips for singles to clarify what they're truly looking for and identify compatible partnersEmotional Awareness for Successful Dating – How understanding and managing emotions can improve dating experiences and lead to more fulfilling relationshipsBuilding Trust and Communication in the Early Stages of Dating – Essential strategies for establishing a strong foundation in new relationships.You can find Jason & Tina Marie Scott:https://www.instagram.com/legendaryrelationship/https://www.youtube.com/@legendaryrelationshiphttps://legendaryrelationship.com/Single? Download our dating app:https://subscribepage.io/ffO65LBuy our dating gameboard:https://p4kdatingapp.com/shop/Want some relationship advice? Leave a voice note:https://www.speakpipe.com/playing4keepsappSupport the show

This Week's Topics:Ryan Reynolds in Early Stages of Exploring a Deadpool/X-Men Team Up Movie ‘X-Men' Movie At Marvel Studios Circling ‘Thunderbolts*' DirectorKevin Feige Feelings on The "Homework Problem"Thunderbolts* Weekend 1 Box OfficeGo to http://OrganicPricedBooks.com and use the Promo Code - MARVELGUA to get $2 off on every order. Use our referral link listed below so they know you are a Marvel Alliance listener: https://organicpricedbooks.com/?ref=beat0bzbb68uSupport The Alliance On Patreon & Get Ad-Free, Exclusive, Early Episodes https://www.patreon.com/guanetwork Geek Ultimate Alliance Network Is Produced By GeekVerse Podcast www.geekverse.ca Network Schedule:Monday: Rangers Alliance (Bi-Weekly)Tuesday: A Walk Through the Multiverse (Bi-Weekly)Wednesday: The Animation NationThursday: Star Wars AllianceFriday: Marvel AllianceSaturday: DC AllianceSunday: World's Finest True Believers (Monthly)Follow the respective shows on Twitter so when they record live on GeekVerse Podcast Network you can join the chat and add to the conversation!

Is your DeFi startup struggling to take off because of lack of interest? If reputation (or the lack thereof) is hurting your chances of getting funding, you need MediaRise's content solution on hand. Find out more at https://mediarise.clientcabin.com/app/defi-distribution MediaRise City: Bronx Address: 5680 Broadway Website: https://mediarise.clientcabin.com/ Email: skeeteadvisorygroup@gmail.com

The Early Stages of a Park Development for Woodside's Filipino Community by Uptown Radio

In this episode, we sit down with Christine Larson, Head of Strategy & Operations at Modern Energy and interim COO at Industrial Sun, to explore how early-stage developers can thrive in a landscape defined by high complexity, capital intensity, and shifting market signals.Christine shares how Modern's model goes beyond funding—providing hands-on operational support like IT and accounting—so founders can focus on what really matters: building and scaling transformative energy projects.We dive into:Why Modern invests in niche, high-complexity infrastructure like green hydrogen and EV fleet chargingHow capital bottlenecks and tariff uncertainty are shaping developer riskWhy utility coordination and contract innovation are now mission-criticalHow partnerships, not just tech, will drive the future of energyChristine and James explore how strategic collaboration—between developers, capital partners, and load customers—is key to unlocking the next generation of clean energy infrastructure.Paces helps developers find and evaluate the sites most suitable for renewable development. Interested in a call with James, CEO @ Paces?

Revolutionizing Nonprofit Fundraising with AI: An Interview with PosterChild.ai CEO Leandrew Robinson In this episode, we delve into the innovative world of nonprofit fundraising with Leandrew Robinson, the CEO and founder of PosterChild.ai. Discover how their peer-to-peer fundraising strategy helped their first customer achieve a 350% increase in individual giving year over year. Leandrew shares his journey from e-commerce to social impact, the importance of authentic storytelling, and how AI can streamline nonprofit operations. Learn about the transformative power of AI in creating and curating content, and get insights into the future of nonprofit fundraising. Whether you're a nonprofit leader or curious about the intersection of AI and social good, this episode is packed with valuable takeaways. 00:00 Introduction to Poster Child's Success 00:45 Meet Lean Andrew Robinson 01:14 The Journey to Poster Child 01:37 The Concept of Crowdsource Storytelling 02:24 From E-commerce to Nonprofits 03:37 The Role of AI in Nonprofit Storytelling 03:49 Challenges in Nonprofit Storytelling 04:46 AI's Impact on Authentic Storytelling 07:30 Future of AI in Nonprofit Fundraising 10:58 Balancing Features and Focus in Startups 15:30 Adoption and Evolution of AI Tools 21:01 Early Adoption and Future Pitfalls 21:58 The Early Stages of AI Integration 24:23 Transitioning from E-commerce to Nonprofit 25:41 Challenges in the Nonprofit Sector 28:44 Effective Fundraising Strategies 34:47 The Importance of Serendipity and Networking 36:35 Rapid Fire Questions 40:36 Final Thoughts and Contact Information

In this episode of our CVC series, Andreas Munk Holm and our CVC in-house expert, Jeppe Høier, talk with Marika King, Head of PINC, the corporate venture arm of Paulig.Marika shares how PINC was born to accelerate core innovation and deliver long-term impact across health, sustainability, and food security. She explains why PINC goes earlier than most CVCs and how they leverage Paulig's R&D and cultural DNA to validate, support, and scale startups. Marika also offers candid reflections on governance structures, founder dynamics, and how her journey through burnout shaped her values as an investor.Here's what's covered:03:10 Early Stage Investments and Validation16:54 Governance and Structure of Pink Ventures24:00 Lessons in Structuring a Corporate Venture Fund26:34 Understanding the Role of a CVC27:03 Misconceptions About CVCs28:49 Flexibility and Patience in CVC Investments31:29 The Importance of Founder-Friendly A

The hosts dissect Attio's AI-native CRM disrupting traditional customer management and examine the surprisingly resilient seed/Series B funding landscape despite economic headwinds. Learn how AI is fundamentally changing go-to-market playbooks, enabling tech companies to scale faster than ever before, and which AI sales tools have genuine staying power.Thanks for tuning in! Join the free Topline Slack channel to connect with 600+ revenue leaders, share insights, and keep the conversation going beyond the podcast!Subscribe to the Topline Newsletter to get the latest industry developments and emerging go-to-market trends delivered to your inbox every Thursday.Tune into The Revenue Leadership Podcast with Kyle Norton every Wednesday. Kyle dives deep into the strategies and tactics that drive success for revenue leaders like Jason Lemkins of SaaStr, Stevie Case of Vanta, and Ron Gabrisko of Databricks.Key Moments:[02:07] AJ's Boating Adventure[04:05] Sam on Pavilion's CMO Summit and Personal Updates[06:56] Marketing and Revenue Insights[10:36] AI in Business[13:34] Economic Sentiment and Business Strategy[33:02] Hiring in Volatile Times[37:04] Compensation Strategies for Sales Teams[40:55] AI in Sales: A Conversation with an AI SDR Founder[48:06] The Future of AI in Sales and Marketing[01:00:15] Novel Uses of AI[01:08:54] Closing Remarks and Shoutouts

Gopi Rangan has invested in 29 early-stage startups from scratch. He shares a simple but powerful approach to picking the right VCs, structuring your pitch (long-term vision + short-term plan + fuzzy mid-term path), and proving you are the sort of founder every pre-seed investor craves. If you're raising a pre-seed or seed, Gopi's tips will make your process faster, more targeted, and a lot less painful.___Why You Should Listen1. The 2-minute test for "real" pre-seed investors – Spot VCs who truly lead early rounds vs. those who waste your time.2. His 3-step framework for finding your perfect lead – Forget the 100 investor pipeline. Zero in on 10 prospects who'll actually write a check.3. How to balance short-term execution with a massive mission – Win over pre-seed VCs by knowing your next 6 months and your 10-year ambition.4. Why "business acumen" beats everything – Gopi explains how it trumps domain expertise or brand-name credentials.5. When to be fuzzy, when to be precise – The counterintuitive approach that shows you're open to customer feedback while still having big vision.____KeywordsPre-seed Funding, Early-Stage VC, Business Acumen, Go-to-Market Strategy, Founder–Investor Fit, Strategic Networking, Seed Round Pitch, Warm Introductions, Mission-Driven Startups, Conviction Investing____(00:00:00) Why Ruthless Prioritization Wins(00:03:29) Why Investing at Pre-seed is Personal(00:08:36) Investing When There Are Still Typos in the Pitch Deck(00:12:23) Spotting Founders with Exceptional Business Acumen(00:17:21) Great Ideas in the Hands of the Right Founder(00:26:29) The Practical Guide to Raising Your Seed RoundSend me a message to let me know what you think!

In this video, we dive into Antler, a global early-stage investor that's backing the world's most ambitious founders and building the fastest-growing portfolio of venture-backed startups across the globe.This video is specifically for founders looking to scale or anyone just curious about how top VCs help startups grow from idea to impact, this video breaks down how Antler supports early-stage startups with funding, resources, and expert guidance to accelerate their journey.

Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the updated recommendations and topics such as when SLNB can be omitted, when ALND is indicated, radiation and systemic treatment decisions after SLNB omission, and the role of SLNB in special circumstances. We discuss the importance of shared decision-making and other ongoing and future de-escalation trials that will expand knowledge in this space. Read the full guideline update, “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update” at www.asco.org/breast-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-00099       Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Ko Un "Clara" Park from Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dr. Mylin Torres from Glenn Family Breast Center at Winship Cancer Institute of Emory University, co-chairs on “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you, it's a pleasure to be here. Brittany Harvey: And before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Torres and Dr. Park, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To start us off, Dr. Torres, what is the scope and purpose of this guideline update on the use of sentinel lymph node biopsy in early-stage breast cancer? Dr. Mylin Torres: The update includes recommendations incorporating findings from trials released since our last published guideline in 2017. It includes data from nine randomized trials comparing sentinel lymph node biopsy alone versus sentinel lymph node biopsy with a completion axillary lymph node dissection. And notably, and probably the primary reason for motivating this update, are two trials comparing sentinel lymph node biopsy with no axillary surgery, all of which were published from 2016 to 2024. We believe these latter two trials are practice changing and are important for our community to know about so that it can be implemented and essentially represent a change in treatment paradigms. Brittany Harvey: It's great to hear about these practice changing trials and how that will impact these recommendation updates. So Dr. Park, I'd like to start by reviewing the key recommendations across all of these six overarching clinical questions that the guideline addressed. So first, are there patients where sentinel lymph node biopsy can be omitted? Dr. Ko Un "Clara" Park: Yes. The key change in the current management of early-stage breast cancer is the inclusion of omission of sentinel lymph node biopsy in patients with small, less than 2 cm breast cancer and a negative finding on preoperative axillary ultrasound. The patients who are eligible for omission of sentinel lymph node biopsy according to the SOUND and INSEMA trial are patients with invasive ductal carcinoma that is size smaller than 2 cm, Nottingham grades 1 and 2, hormone receptor-positive, HER2-negative in patients intending to receive adjuvant endocrine therapy, and no suspicious lymph nodes on axillary ultrasound or if they have only one suspicious lymph node, then the biopsy of that lymph node is benign and concordant according to the axillary ultrasound findings. The patients who are eligible for sentinel lymph node biopsy omission according to the SOUND and INSEMA trials were patients who are undergoing lumpectomy followed by whole breast radiation, especially in patients who are younger than 65 years of age. For patients who are 65 years or older, they also qualify for omission of sentinel lymph node biopsy in addition to consideration for radiation therapy omission according to the PRIME II and CALGB 9343 clinical trials. And so in those patients, a more shared decision-making approach with the radiation oncologist is encouraged. Brittany Harvey: Understood. I appreciate you outlining that criteria for when sentinel lymph node biopsy can be omitted and when shared decision making is appropriate as well. So then, Dr. Torres, in those patients where sentinel lymph node biopsy is omitted, how are radiation and systemic treatment decisions impacted? Dr. Mylin Torres: Thank you for that question. I think there will be a lot of consternation brought up as far as sentinel lymph node biopsy and the value it could provide in terms of knowing whether that lymph node is involved or not. But as stated, sentinel lymph node biopsy actually can be safely omitted in patients with low risk disease and therefore the reason we state this is that in both SOUND and INSEMA trial, 85% of patients who had a preoperative axillary ultrasound that did not show any signs of a suspicious lymph node also had no lymph nodes involved at the time of sentinel node biopsy. So 85% of the time the preoperative ultrasound is correct. So given the number of patients where preoperative ultrasound predicts for no sentinel node involvement, we have stated within the guideline that radiation and systemic treatment decisions should not be altered in the select patients with low risk disease where sentinel lymph node biopsy can be omitted. Those are the patients who are postmenopausal and age 50 or older who have negative findings on preoperative ultrasound with grade 1 or 2 disease, small tumors less than or equal to 2 cm, hormone receptor-positive, HER2-negative breast cancer who undergo breast conserving therapy. Now, it's important to note in both the INSEMA and SOUND trials, the vast majority of patients received whole breast radiation. In fact, within the INSEMA trial, partial breast irradiation was not allowed. The SOUND trial did allow partial breast irradiation, but in that study, 80% of patients still received whole breast treatment. Therefore, the preponderance of data does support whole breast irradiation when you go strictly by the way the SOUND and INSEMA trials were conducted. Notably, however, most of the patients in these studies had node-negative disease and had low risk features to their primary tumors and would have been eligible for partial breast irradiation by the ASTRO Guidelines for partial breast treatment. So, given the fact that 85% of patients will have node-negative disease after a preoperative ultrasound, essentially what we're saying is that partial breast irradiation may be offered in these patients where omission of sentinel node biopsy is felt to be safe, which is in these low risk patients. Additionally, regional nodal irradiation is something that is not indicated in the vast majority of patients where omission of sentinel lymph node biopsy is prescribed and recommended, and that is because very few of these patients will actually end up having pathologic N2 disease, which is four or more positive lymph nodes. If you look at the numbers from both the INSEMA and the SOUND trial, the number of patients with pathologic N2 disease who did have their axilla surgically staged, it was less than 1% in both trials. So, in these patients, regional nodal irradiation, there would be no clear indication for that more aggressive and more extensive radiation treatment. The same principles apply to systemic therapy. As the vast majority of these patients are going to have node-negative disease with a low risk primary tumor, we know that postmenopausal women, even if they're found to have one to three positive lymph nodes, a lot of the systemic cytotoxic chemotherapy decisions are driven by genomic assay score which is taken from the primary tumor. And therefore nodal information in patients who have N1 disease may not be gained in patients where omission of sentinel lymph node biopsy is indicated in these low risk patients. 14% of patients have 1 to 3 positive lymph nodes in the SOUND trial and that number is about 15% in the INSEMA trial. Really only the clinically actionable information to be gained is if a patient has four or more lymph nodes or N2 disease in this low risk patient population. So, essentially when that occurs it's less than 1% of the time in these patients with very favorable primary tumors. And therefore we thought it was acceptable to stand by a recommendation of not altering systemic therapy or radiation recommendations based on omission of sentinel nodes because the likelihood of having four more lymph nodes is so low. Dr. Ko Un "Clara" Park: I think one thing to add is the use of CDK4/6 inhibitors to that and when we look at the NATALEE criteria for ribociclib in particular, where node-negative patients were included, the bulk majority of the patients who were actually represented in the NATALEE study were stage III disease. And for stage I disease to upstage into anatomic stage III, that patient would need to have pathologic N2 disease. And as Dr. Torres stated, the rate of having pathologic N2 disease in both SOUND and INSEMA studies were less than 1%. And therefore it would be highly unlikely that these patients would be eligible just based on tumor size and characteristics for ribociclib. So we think that it is still safe to omit sentinel lymph node biopsy and they would not miss out, if you will, on the opportunity for CDK4/6 inhibitors. Brittany Harvey: Absolutely. I appreciate you describing those recommendations and then also the nuances of the evidence that's underpinning those recommendations, I think that's important for listeners. So Dr. Park, the next clinical question addresses patients with clinically node negative early stage breast cancer who have 1 or 2 sentinel lymph node metastases and who will receive breast conserving surgery with whole breast radiation therapy. For these patients, is axillary lymph node dissection needed? Dr. Ko Un "Clara" Park: No. And this is confirmed based on the ACOSOG Z0011 study that demonstrated in patients with 1 to 3 positive sentinel lymph node biopsy when the study compared completion axillary lymph node dissection to no completion axillary lymph node dissection, there was no difference. And actually, the 10-year overall survival as reported out in 2017 and at a median follow up of 9.3 years, the overall survival again for patients treated with sentinel lymph node biopsy alone versus those who were treated with axillary lymph node dissection was no different. It was 86.3% in sentinel lymph node biopsy versus 83.6% and the p-value was non-inferior at 0.02. And so we believe that it is safe for the select patients who are early stage with 1 to 2 positive lymph nodes on sentinel lymph node biopsy, undergoing whole breast radiation therapy to omit completion of axillary lymph node dissection. Brittany Harvey: Great, I appreciate you detailing what's recommended there as well. So then, to continue our discussion of axillary lymph node dissection, Dr. Torres, for patients with nodal metastases who will undergo mastectomy, is axillary lymph node dissection indicated? Dr. Mylin Torres: It's actually not and this is confirmed by two trials, the AMAROS study as well as the SENOMAC trial. And in both studies, they compared a full lymph node dissection versus sentinel lymph node biopsy alone in patients who are found to have 1 to 2 positive lymph nodes and confirmed that there was no difference in axillary recurrence rates, overall survival or disease-free survival. What was shown is that with more aggressive surgery completion axillary lymph node dissection, there were higher rates of morbidity including lymphedema, shoulder pain and paresthesias and arm numbness, decreased functioning of the arm and so there was only downside to doing a full lymph node dissection. Importantly, in both trials, if a full lymph node dissection was not done in the arm that where sentinel lymph node biopsy was done alone, all patients were prescribed post mastectomy radiation and regional nodal treatment and therefore both studies currently support the use of post mastectomy radiation and regional nodal treatment when a full lymph node dissection is not performed in these patients who are found to have N1 disease after a sentinel node biopsy. Brittany Harvey: Thank you. And then Dr. Park, for patients with early-stage breast cancer who do not have nodal metastases, can completion axillary lymph node dissection be omitted? Dr. Ko Un "Clara" Park: Yes, and this is an unchanged recommendation from the earlier ASCO Guidelines from 2017 as well as the 2021 joint guideline with Ontario Health, wherein patients with clinically node-negative early stage breast cancer, the staging of the axilla can be performed through sentinel lymph nodal biopsy and not completion axillary lymph node dissection. Brittany Harvey: Understood. So then, to wrap us up on the clinical questions here, Dr. Park, what is recommended regarding sentinel lymph node biopsy in special circumstances in populations? Dr. Ko Un "Clara" Park: One key highlight of the special populations is the use of sentinel lymph node biopsy for evaluation of the axilla in clinically node negative multicentric tumors. While there are no randomized clinical trials evaluating specifically the role of sentinel lymph nodal biopsy in multicentric tumors, in the guideline, we highlight this as one of the safe options for staging of the axilla and also for pregnant patients, these special circumstances, it is safe to perform sentinel lymph node biopsy in pregnant patients with the use of technetium - blue dye should be avoided in this population. In particular, I want to highlight where sentinel lymph node biopsy should not be used for staging of the axilla and that is in the population with inflammatory breast cancer. There are currently no studies demonstrating that sentinel lymph node biopsy is oncologically safe or accurate in patients with inflammatory breast cancer. And so, unfortunately, in this population, even after neoadjuvant systemic therapy, if they have a great response, the current guideline recommends mastectomy with axillary lymph node dissection. Brittany Harvey: Absolutely. I appreciate your viewing both where sentinel lymph node can be offered in these special circumstances in populations and where it really should not be used. So then, Dr. Torres, you talked at the beginning about how there's been these new practice changing trials that really impacted these recommendations. So in your view, what is the importance of this guideline update and how does it impact both clinicians and patients? Dr. Mylin Torres: Thank you for that question. This update and these trials that inform the update represent a significant shift in the treatment paradigm and standard of care for breast cancer patients with early-stage breast cancer. When you think about it, it seems almost counterintuitive that physicians and patients would not want to know if a lymph node is involved with cancer or not through sentinel lymph node biopsy procedure. But what these studies show is that preoperative axillary ultrasound, 85% of the time when it's negative, will correctly predict whether a sentinel lymph node is involved with cancer or not and will also be negative. So if you have imaging that's negative, your surgery is likely going to be negative. Some people might ask, what's the harm in doing a sentinel lymph node biopsy? It's important to recognize that upwards of 10% of patients, even after sentinel lymph node biopsy will develop lymphedema, chronic arm pain, shoulder immobility and arm immobility. And these can have a profound impact on quality of life. And if there is not a significant benefit to assessing lymph nodes, particularly in someone who has a preoperative axillary ultrasound that's negative, then why put a patient at risk for these morbidities that can impact them lifelong? Ideally, the adoption of omission of sentinel lymph node biopsy will lead to more multidisciplinary discussion and collaboration in the preoperative setting especially with our diagnostic physicians, radiology to assure that these patients are getting an axillary ultrasound and determine how omission of sentinel lymph node biopsy may impact the downstream treatments after surgery, particularly radiation and systemic therapy decisions, and will be adopted in real world patients, and how clinically we can develop a workflow where together we can make the best decisions for our patients in collaboration with them through shared decision making. Brittany Harvey: Absolutely. It's great to have these evidence-based updates for clinicians and patients to review and refer back to. So then finally, Dr. Park, looking to the future, what are the outstanding questions and ongoing trials regarding sentinel lymph node biopsy in early-stage breast cancer? Dr. Ko Un "Clara" Park: I think to toggle on Dr. Torres's comment about shared decision making, the emphasis on that I think will become even more evident in the future as we incorporate different types of de-escalation clinical studies. In particular, because as you saw in the SOUND and INSEMA studies, when we de-escalate one modality of the multimodality therapy, i.e., surgery, the other modalities such as radiation therapy and systemic therapy were “controlled” where we were not de-escalating multiple different modalities. However, as the audience may be familiar with, there are other types of de-escalation studies in particular radiation therapy, partial breast irradiation or omission of radiation therapy, and in those studies, the surgery is now controlled where oftentimes the patients are undergoing surgical axillary staging. And conversely when we're looking at endocrine therapy versus radiation therapy clinical trials, in those studies also the majority of the patients are undergoing surgical axillary staging. And so now as those studies demonstrate the oncologic safety of omission of a particular therapy, we will be in a position of more balancing of the data of trying to select which patients are the safe patients for omission of certain types of modality, and how do we balance whether it's surgery, radiation therapy, systemic therapy, endocrine therapy. And that's where as Dr. Torres stated, the shared decision making will become critically important. I'm a surgeon and so as a surgeon, I get to see the patients oftentimes first, especially when they have early-stage breast cancer. And so I could I guess be “selfish” and just do whatever I think is correct. But whatever the surgeon does, the decision does have consequences in the downstream decision making. And so the field really needs to, as Dr. Torres stated earlier, rethink the workflow of how early-stage breast cancer patients are brought forth and managed as a multidisciplinary team. I also think in future studies the expansion of the data to larger tumors, T3, in particular,reater than 5 cm and also how do we incorporate omission in that population will become more evident as we learn more about the oncologic safety of omitting sentinel lymph node biopsy. Dr. Mylin Torres: In addition, there are other outstanding ongoing clinical trials that are accruing patients right now. They include the BOOG 2013-08 study, SOAPET, NAUTILUS and the VENUS trials, all looking at patients with clinical T1, T2N0 disease and whether omission of sentinel lymph node biopsy is safe with various endpoints including regional recurrence, invasive disease-free survival and distant disease-free survival. I expect in addition to these studies there will be more studies ongoing even looking at the omission of sentinel lymph node biopsy in the post-neoadjuvant chemotherapy setting. And as our imaging improves in the future, there will be more studies improving other imaging modalities, probably in addition to axillary ultrasound in an attempt to accurately characterize whether lymph nodes within axilla contain cancer or not, and in that context whether omission of sentinel lymph node biopsy even in patients with larger tumors post-neoadjuvant chemotherapy may be done safely and could eventually become another shift in our treatment paradigm. Brittany Harvey: Yes. The shared decision making is key as we think about these updates to improve quality of life and we'll await data from these ongoing trials to inform future updates to this guideline. So I want to thank you both so much for your extensive work to update this guideline and thank you for your time today. Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you. Dr. Ko Un "Clara" Park: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

I'm pulling back the curtain on the three biggest mistakes that cause early-stage food entrepreneurs to struggle and often fail. Drawing from my experience over 7+ years helping hundreds of food businesses launch and scale, I give you an honest look at why so many passionate food makers hit roadblocks despite having amazingly delicious products.You'll discover why listening to everyone's conflicting opinions leads to confusion rather than clarity, how spreading yourself too thin across multiple sales channels sabotages your momentum, and the surprising cost of operating without a proper long-term plan or budget. More importantly, I share practical solutions for each of these pitfalls, including how to filter advice, strategically choose your sales channels, and create a vision-driven plan that actually works.Whether you're still in the dreaming phase or already knee-deep in your food business journey, this episode delivers the tough love and actionable strategies you need to avoid common traps and set your business up for sustainable success. Don't miss this essential guide to navigating the early stages of your food business with confidence!Stop the endless research and overwhelm! Know exactly what each sales channel looks like for success and create a roadmap for your unique business - join me in the Sales Channel Challenge - 3 days April 15, 16 and 17. Reserve your space for just $27 at https://www.foodbizsuccess.com/challenge MAKE A BIG LEAP THIS YEAR! Commit to the support and accountability you need to create a beautiful business! Get Food Business Success to launch and scale to $100K guaranteed Scale your existing business to $300K in 2025 with the financial and operational foundations and become the CEO of your biz in Master Your Business Pick up your copy of "Key Ingredients" on Amazon here. Check out my YouTube channel at www.foodbiz.tube for how to videos to start and grow a packaged food business.

Synopsis: Building in biotech isn't for the faint of heart—especially during a market downturn. But that's exactly when Steve Tregay, Managing Partner at Mission BioCapital, thrives. A seasoned entrepreneur and founder of Forma Therapeutics, Steven has navigated biotech's toughest cycles—and emerged stronger each time. Hosted by Rahul Chaturvedi, this conversation dives into what it really takes to launch and scale biotech companies: from mastering the evolution of the CEO role to raising nearly $900M through strategic partnerships, to knowing when it's time to pass the torch. Steve also shares how Mission BioCapital is rewriting the playbook for early-stage innovation through its Platinum Program, offering $500K and lab access to science founders ready to launch bold new ideas. Real talk, real strategies, and a blueprint for building lasting biotech companies—especially when its hardest. Biography: Steve Tregay, PhD is a Managing General Partner based in our Cambridge office. He focuses on new therapeutics investments with a particular emphasis on company creation opportunities as well as on overall management of the firm. Within the Mission BioCapital portfolio, he is currently founding CEO and board member of Arclight Therapeutics, LLC, a founding board member at Jupiter BioVentures LLC, and has board roles at Vedere Bio and Nocion Therapeutics. In addition, Steve serves as Chairman of the Board of Directors at LabCentral. He is a Harvard Blavatnik Biomedical Accelerator Advisory Committee member and is a member of the board of advisors for the non-profit Life Sciences Cares. Previously, Steve was the Founder and CEO of FORMA Therapeutics. Additional roles held prior to his engagement at FORMA include Managing Director for the Novartis Venture Fund and Executive Director & Head of Strategic Alliances for Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. Prior to Novartis, he held roles in research and business development at Array BioPharma. Steve received his doctoral and Master's degrees in organic chemistry from Harvard University and a Bachelor's from Davidson College.

Are 100x multiples achievable in Water Tech when no-one ever reached 10x? Peter Yolles (Echo River Capital) believes so... and he's on track to prove it!How? Listen to this!More #water insights? Connect with me on Linkedin: https://www.linkedin.com/in/antoinewalter1/

Growth doesn't have to mean being everywhere at once or chasing every shiny new tactic.In this episode of No Hacks, I talk with Ward van Gasteren — one of Europe's first growth hackers — about how to grow smarter, not louder. Ward shares his go-to method for helping early-stage startups: the 1-1-1 Framework — one audience, one channel, one message.We dig into how founders and product teams can stop spreading themselves too thin, avoid early-stage overwhelm, and finally find traction through focus. Ward explains the difference between growth and traditional marketing, how to approach experimentation, and why most companies waste time on strategies that don't serve their stage.Whether you're building a company, a product, or even a podcast — this conversation will help you cut through the noise and grow with clarity.Topics Covered:How to stop doing too much and focus on what worksThe 1-1-1 Framework for early-stage clarityWhy founders waste time on channels that aren't readyThe role of experimentation beyond A/B testingChoosing the right growth metrics and north starWhy organic social is rarely a growth engineBuilding scalable systems after early tractionAI's impact on speed (but not necessarily quality)How podcast growth follows the same principles as startup growthAbout the Guest:Ward van Gasteren is a growth consultant and one of Europe's first professional growth hackers. Through his platform Grow with Ward, he helps early-stage startups create growth strategies that actually work — without burning out in the process.Ward has worked with companies across industries to simplify how they think about growth, run smarter experiments, and scale what's already working. His 1-1-1 Framework has helped founders build real traction by focusing on the right things — not everything.Timestamps:00:00:00 – What does a growth consultant really do?00:06:07 – Breaking down the 1-1-1 Framework: one audience, one channel, one message00:10:27 – Brand-building vs. selling: when organic social actually helps00:15:30 – Ward's favorite growth tool (and why he'd ditch GA4)00:20:07 – Growth vs. Marketing: different teams, different goals00:25:08 – How AI tools help with speed, but not necessarily with strategy00:30:24 – Getting honest customer feedback and applying “The Mom Test”00:35:16 – Ward's growth program and where to follow his workConnect with Ward: → Website: https://growwithward.com → LinkedIn: https://www.linkedin.com/in/wardvangasteren/---If you enjoyed the episode, please share it with a friend!No Hacks websiteYouTubeLinkedInInstagram

In this episode of the SaaS Sessions podcast, Jacob Bank, founder of Relay.app, shares his journey from academia to startup founder, discussing the challenges of building a product in the AI space. He emphasizes the importance of validating ideas, finding early customers, and experimenting with various marketing channels. Jacob also highlights the significance of cohort retention as a measure of product-market fit and the need to balance innovation with competition in a rapidly evolving market.Key Takeaways –1. You're not failing - your distribution isBuilding is easy; getting customers is the battlefield.Early channels (Reddit, network, cold email) only take you so far.Most startup advice is outdated or irrelevant to your context - test everything yourself.2. Validate with precision, not egoThe Mom Test changed how Jacob gathered honest feedback.10 well-run interviews can kill or greenlight an idea.Getting “likes” is not validation - retention and willingness to pay are.3. Every growth stage needs a new motion0 → 10: Scrappy hustle (Reddit, LinkedIn DMs, direct outreach).10 → 100: Partner marketing, SEO, and high-intent blog content.100 → 1000: Viral LinkedIn content + YouTube for education + community-led growth.4. PMF isn't hype - it's cohort retentionRetention is the only true sign of product-market fit.Competitive pressure is a forcing function to build better products.Don't be afraid to pick a fight in a crowded space - just know your edge.Connect with Jacob Bank:

It's not uncommon for brands to scale mostly as B2B enterprises with minimal emphasis on sophisticated consumer marketing. When product design carries you that far, it can be easy to overlook the marketing department. Then, when you turn to ask them for acceleration, you realize you do not have the right team at all. Or, even worse, you don't even believe. For the founders who delay and doubt the power of marketing, please have a listen. Your Host: Dr. James F. Richardson of Premium Growth Solutions, LLC www.premiumgrowthsolutions.com Please send feedback on this or other episodes to: admin@premiumgrowthsolutions.com

Künstliche Intelligenz verändert alles – und wer jetzt richtig handelt, kann davon massiv profitieren. In diesem Video zeige ich dir meine 3 aktuellen Strategien, wie ich KI nutze, um mein Portfolio, mein Unternehmen und meine Prozesse zu optimieren:

Get practical answers to questions COOs are asking—about SOPs, staffing ahead of growth, and managing disengaged employees. In this Q&A episode of The Right-Hand Roadmap, Megan Long tackles real-world questions from second-in-command leaders navigating fast growth, resource constraints, and team dynamics. Whether you're wondering when to systematize your startup, how to staff for a 30% growth forecast, or what to do with employees who are just clocking in and out, this episode has guidance you can apply immediately. Megan draws on years of experience working inside and alongside founder-led businesses to help you set smart priorities and avoid common missteps. You'll hear all about: 00:00 – Introduction to the Q&A format and how to submit your own questions 01:47 – Q1: Prioritizing SOPs and processes at an early-stage company with ambitious growth goals 02:11 – Why sales and marketing systems must come before internal process-building 03:10 – Strategic planning example: focusing on partnerships and lead gen over documentation 04:08 – A warning: 300% growth will break your current systems—so build flexibly 05:08 – Story: Megan's mistake of over-documenting accounting procedures too early 06:47 – Challenge your CEO on whether SOPs are the most urgent need right now 07:08 – Q2: Should you staff up in anticipation of growth or wait until overwhelmed? 08:16 – The cultural and operational risks of premature hiring 08:46 – Megan's rule of thumb: distinguish between proven vs. unproven growth 09:04 – Second First benchmarking data: turnover and revenue trends across members 10:07 – Forecasting in the post-2020 era: why historical data can be misleading Rate, review & follow on Apple Podcasts Click Here to Listen! OR WATCH ON YOUTUBE If you haven't already done so, follow the podcast to make sure you never miss a value-packed episode. Links mentioned in the episode: Second First Membership Second First One-on-One Coaching Second First on Instagram Second First on LinkedIn Megan Long on LinkedIn

Welcome back to the Alt Goes Mainstream podcast.Today's episode dives into the details of distribution and how to build a high-performing global business to serve the wealth channel across brands and strategies.John Sweeney is the Chief Executive Officer of Brookfield Oaktree Wealth Solutions, a business unit that was created to harmonize the distribution efforts across the Brookfield and Oaktree brands. He previously served as Head of US Business Development and Sales for Brookfield Oaktree Wealth Solutions and was a Managing Director and Head of the Americas intermediary business at Oaktree Capital. He also served as president of Oaktree Funds from 2014-2018.Before joining the alternative asset manager side of the business, John had extensive experience working in alternative investments roles at private banks. Before joining Oaktree in 2013, he was a Managing Director and Head of Product Management and Development for the alternative investments business at Morgan Stanley. Prior to that, he was the Head of Product Management in the US for the alternative investments business of the Citi Private Bank.John and I had a fascinating and informative discussion. We covered:How John is building Brookfield Oaktree's wealth business.The benefits of scale.Wisdom from John's Oaktree colleague Howard Marks.How advisor education is critical to the adoption of private markets.Thanks John for coming on the show to share your wisdom and views on private markets and working with the wealth channel.Subscribe to Alt Goes Mainstream to receive the weekly newsletter every Sunday and all of AGM's podcasts.A word from AGM podcast sponsor, Ultimus Fund SolutionsThis episode of Alt Goes Mainstream is brought to you by Ultimus Fund Solutions, a leading full-service fund administrator for asset managers in private and public markets. As private markets continue to move into the mainstream, the industry requires infrastructure solutions that help funds and investors keep pace. In an increasingly sophisticated financial marketplace, investment managers must navigate a growing array of challenges: elaborate fund structures, specialized strategies, evolving compliance requirements, a growing need for sophisticated reporting, and intensifying demands for transparency.To assist with these challenging opportunities, more and more fund sponsors and asset managers are turning to Ultimus, a leading service provider that blends high tech and high touch in unique and customized fund administration and middle office solutions for a diverse and growing universe of over 450 clients and 1,800 funds, representing $500 billion assets under administration, all handled by a team of over 1,000 professionals. Ultimus offers a wide range of capabilities across registered funds, private funds and public plans, as well as outsourced middle office services. Delivering operational excellence, Ultimus helps firms manage the ever-changing regulatory environment while meeting the needs of their institutional and retail investors. Ultimus provides comprehensive operational support and fund governance services to help managers successfully launch retail alternative products.Visit www.ultimusfundsolutions.com to learn more about Ultimus' technology enhanced services and solutions or contact Ultimus Executive Vice President of Business Development Gary Harris on email at gharris@ultimusfundsolutions.com.We thank Ultimus for their support of alts going mainstream.Show Notes00:00 Introduction to our Sponsor, Ultimus Fund Solutions01:55 Welcome to Alt Goes Mainstream02:06 Introduction to John Sweeney03:58 John's Early Career at Morgan Stanley04:34 Evolution of Alternative Investments05:15 Impact of Technology on Private Markets06:42 Service and Distribution Strategy09:33 Building Brookfield Oaktree's Wealth Business11:16 Brookfield and Oaktree Acquisition12:42 Creating Investment Solutions14:07 Understanding the Wealth Channel15:05 Global Distribution Strategy17:52 Importance of Brand and Service19:06 Effective Client Engagement21:09 Advisors vs. Institutional Investors22:27 Evergreen Funds and Distribution25:09 Balancing Content and Engagement27:15 Investment Philosophy and Market Context29:36 Risk Control and Consistency30:53 Generational Wealth Transfer31:40 Educating the Next Generation of Investors32:04 Long-Term Track Record and Conclusion32:18 Delivering Returns and Long-Term Success32:31 Accessing Evergreen Funds32:45 Compounding Returns Over Time32:52 Thinking in Decades32:57 Private Credit and Economic Cycles33:16 Experience and Results33:41 Brand and Experience in Private Markets34:55 Marketing and History35:12 Brookfield Real Estate Introduction35:34 Oaktree's Credit Roots35:55 Integrating Two Brands36:15 Building Solutions and Partnerships39:03 Global Presence and Scale39:13 Navigating Wealth Channel Conversations40:34 Competing in Various Deal Sizes41:16 Exploring Secondary Markets41:56 Private Capital Opportunities42:50 Survey Insights on Alternatives44:04 Global Wealth Channel Strategies44:44 Regional Strategies and Local Teams47:42 Building a Culture of Shared Success48:42 Educating Advisors49:43 Early Stages of Wealth Channel51:41 Model Portfolios and Solutions56:32 The Appeal of Music Royalties and Human Connection58:14 Conclusion and Final ThoughtsEditing and post-production work for this episode was provided by The Podcast Consultant.

This week, our host, Erica Wenger, shares a number of practical and unconventional tips on how to fundraise effectively as an early-stage founder!In this episode, Erica breaks down the fundraising process beyond the typical advice, offering insights on how to approach investors, craft a compelling narrative, and stand out in a crowded market. She challenges common misconceptions about fundraising and highlights creative strategies founders can use to secure capital—whether through unconventional networking, alternative funding sources, or leveraging unique market positioning.If you're an early-stage founder navigating the fundraising landscape, this episode is packed with actionable insights to help you raise capital with confidence!Follow Us!Erica Wenger: @erica_wengerDear Twentysomething: @deartwentysomethingRead less

About the Episode:Eugene Khayman is the COO of Million Dollar Sellers (MDS), an exclusive community for top Amazon entrepreneurs that he helped grow from a humble Facebook group into a thriving six-figure membership of 700 members generating $11 billion in annual sales.In this episode of "Uploading...", Eugene shares the organic journey of building MDS alongside running his own Amazon brand. He discusses key strategies that made MDS successful, such as their "give more, get more" philosophy, setting a high bar for membership to filter out noise, and delivering immense value that justifies the $7,500 annual membership fee.Eugene also unpacks the business model powering MDS, including multiple revenue streams from membership, partnerships, affiliates, and events. He emphasizes the importance of member-only perks, local chapters, and a robust software platform to organize resources and drive engagement in a community. Finally, Eugene offers advice for content creators looking to launch their own paid communities.Today, we'll cover:- How MDS grew organically from a humble Facebook group to a thriving community- The "Give More, Get More" philosophy that drives member engagement and success- Strategies for filtering out noise and maintaining a high-quality, focused community- The business model behind MDS and why people pay over $7,000 a year to be part of the network- Eugene's insights on scaling communities while maintaining their identity and core values- Tips for building and monetizing your own niche membership communityWhat You'll Learn1. How to Start a Community from Scratch2. Strategies for Organic Community Growth 3. How to Filter Noise in Early Stages of Community4. When and How to Monetize a Community5. Thriving vs. Dead Communities6. Software for Managing Communities7. Application and Onboarding Process for Established Communities8. Tips for Creators on Building and Monetizing a CommunityTimestamps00:00 Intro and background on Eugene and Million Dollar Sellers (MDS) 04:45 Current stats of MDS community: revenue, members, ticket price 06:45 Starting a community organically and verifying/filtering members 08:33 Monetization: when to do it and how to create value14:44 Where to host a new community and who to bring in17:53 Seeding a new community: starting conversations and keeping it alive24:02 Application process and onboarding new members to MDS now 26:55 Where MDS community is going; chapters for local connections 30:30 Platforms used to run MDS community; GroupOS app development33:44 Opportunities for content creators to monetize via communities 38:33 Q&A: Strategies for specific community examples from audience 44:00 Building a wait list and leveraging existing audience for a community 46:02 Options for immediately monetizing a new community 50:44 Turning virality into community; setting criteria and values 55:15 Wrap-up; where to find Eugene on socialBuilding Engaged Communities: “I think your first objective should always be like that core group of the founding members. For us I think it was like 150 members before we started actually monetizing. But you know, I would say you want to get to 100 members, you want to have at least 40, 50 die hard members that are engaging in there every single day. You want to get at least five to 10 conversations happening a day. If somebody can ask a question and have it answered that same day like that, that's the value creation right there, right? You don't want to be the one, you yourself answering every single question because you yourself, you don't know everything.” — Eugene Khayman, 00:08:33 → 00:09:25Monetizing and Scaling a Community: “Whenever somebody starts making a profit because of others, there's going to be some level of, like, why are we doing this? And there's also going to be that, that hesitation to grow. Everybody's going to be like, 'We're so great, we don't need more people.' Right? And we've crossed that bar—100 members, 200 members, 400 members—there's always that, ‘Oh, we're too big, we're too big, we're too big.' And you're going to get that pushback. The biggest thing that I think that helped us do it together is one, once we started monetizing, we started putting all of that money back into more events and more resources, building a team… Once you start adding back value by hiring people that help keep things organized, putting on calls regularly, doing events regularly, you'll get that respect from those members, those existing members. And then the new people that are coming in, you have to show that these new people actually bring value to the community.” — Eugene Khayman, 00:11:33 → 00:13:03Show notes powered by Castmagic---Have any questions about the show or topics you'd like us to explore further?Shoot us a DM; we'd love to hear from you.Want the weekly TL;DR of tips delivered to your mailbox?Check out our newsletter here.Follow us for content, clips, giveaways, & updates!Castmagic InstagramCastmagic TwitterCastmagic LinkedIn  ---Blaine Bolus - Co-Founder of CastmagicRamon Berrios - Co-Founder of CastmagicEugene Khayman - COO of Million Dollar Sellers

In this episode of Thinking Thoracic, co-host Dr. Jeff Yang welcomes Dr. Gavitt Woodard and Dr. Christopher Seder to discuss their recent research on lobectomy versus sublobar resection for early-stage non-small cell lung cancer. Their studies, leveraging data from The STS General Thoracic Surgery Database, provide valuable insights into the long-term survival outcomes of these surgical approaches. Hear from Dr. Woodard on how her study, recognized as the Richard E. Clark Memorial Paper, aimed to evaluate patient populations that were not well represented in prior randomized trials, such as older adults and those with poorer pulmonary function. Dr. Seder explains how his research took a complementary approach, examining over 32,000 patients from 2012 to 2022, with a focus on distinguishing the survival outcomes between lobectomy, segmentectomy, and wedge resection.   

James Peck leads Cooper Parry's Tech and High Growth Tax Team, specializing in supporting venture and PE-backed businesses as they scale from Early Stage through various funding rounds and prepare for liquidity events.  Before joining Cooper Parry, he was at Grant Thornton, where he headed their Fast Growth Technology Tax Team.  Passionate about fostering growth and innovation, James has also mentored numerous tech companies through programs like Wayra and Microsoft Accelerator, helping them navigate the challenges of scaling operations, growing internationally, dealing with the pain points of working in a constantly changing environment, and supporting thousands of companies through fundraising and liquidity events. In this episode, you'll hear about: Insights from James Peck on tech startups navigating tax complexities and international expansion. Impact of UK tax changes on AI-driven tech enterprises and the potential need for overseas expansion. Importance of creative, practical guides like Cooper Perry's comic book for US market entry. Strategic considerations for UK tech firms expanding into the US, including leadership and timing. Analysis of forming Delaware corporations and the necessity of a "Delaware flip" for securing US investment. Tax implications and alternative structures for cross-border tech companies aiming for smoother international growth. Follow and Review: We'd love for you to follow us if you haven't yet. Click that purple '+' in the top right corner of your Apple Podcasts app. We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select “Ratings and Reviews” and “Write a Review” then a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast. Supporting Resources: Linkedin - https://www.linkedin.com/in/jamespeck360/ Website - https://www.cooperparry.com/people/james-peck/ https://www.cooperparry.com/  https://online.flippingbook.com/view/362241495/  Alcorn Immigration Law: Subscribe to the monthly Alcorn newsletter Sophie Alcorn Podcast: Episode 16: E-2 Visa for Founders and Employees Episode 19: Australian Visas Including E-3 Episode 20: TN Visas and Status for Canadian and Mexican Citizens Immigration Options for Talent, Investors, and Founders Immigration Law for Tech Startups eBook

Are you up to date on the most optimal management of patients with early-stage ALK-positive non-small cell lung cancer (NSCLC)? Credit available for this activity expires: 3/24/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/preeclampsia-biomarker-screening-every-trimester-2025a100065r?ecd=bdc_podcast_libsyn_mscpedu

Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of prostate cancer with Dr. Alan Bryce, Chief Clinical Officer and GU Medical Oncologist from City of Hope. In this episode, we explore: •⁠  ⁠The treatment paradigm for early-stage prostate cancer, including the role of active surveillance and the use of abiraterone based on the STAMPEDE trial. •⁠  ⁠The importance of understanding risk factors and treatment options for low, intermediate, and high-risk patients. •⁠  ⁠The implications of PET-PSMA imaging versus conventional CT modalities in staging and treatment decisions. •⁠  ⁠The management of biochemical recurrent disease and the significance of PSA doubling time in treatment planning. •⁠  ⁠The role of PARP inhibitors in patients with HRR mutations and the nuances of selecting appropriate therapies. •⁠  ⁠Strategies for managing metastatic disease, including the use of Lutetium-177 (Pluvicto) and cabazitaxel. Dr. Bryce provides a masterclass on navigating the complexities of prostate cancer treatment, emphasizing the need to balance between over-treatment in early disease and under-treatment in metastatic cases. YouTube: https://youtu.be/Zfu-yGmH0rg Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ If you find this episode helpful, please share it with your colleagues and leave us a review! Don't forget to check out our other episodes in the GU treatment algorithm series, including discussions on renal cell carcinoma and bladder cancer.

Supercharge your analysis with AI! Get 15% of your membership with our special link here: https://finchat.io/csi/The Nvidia GTC Keynote from Jensen Huang was packed full of data for investors. Is the AI boom over? Or is Nvidia's value proposition to customers only just starting? Chip Stock Investors Nick and Kasey break down a pivotal moment in the GTC event, and discuss whether the AI data center trade will re-accelerate or not.Sign Up For Our Newsletter: https://mailchi.mp/b1228c12f284/sign-up-landing-page-short-formJoin us on Discord with Semiconductor Insider: https://ko-fi.com/chipstockinvestor/tiersSafeguard your personal information with Aura's monitoring service – try it free for two weeks and see where your data might be lurking: https://aura.com/chipstockinvestor

When you've built a wildly successful business and suddenly feel the urge to pivot, what do youdo? In this candid solo episode, host Danielle McCleerey shares her personal experiencenavigating a massive business shift—while already running a thriving six and seven-figureenterprise. If you've ever felt the pull to evolve but feared the unknown, this episode is yourpermission slip to trust your intuition, embrace transformation, and move forward with clarity.Danielle also unpacks the emotional, financial, and strategic realities of pivoting at a high level,why nervous system regulation is key, and what most people don't realize about making bigcareer shifts.

Axel Merk discusses the gold market continued move higher, the impact of geopolitical events on gold prices, and investment strategies for gold mining stocks. He emphasizes the importance of understanding the financial system's dynamics and the potential for significant changes in the market. The discussion also covers the challenges and opportunities in gold mining investments, particularly in the context of economic downturns and the need for good management teams in mining companies.

Senior NBA Writer for The Athletic, Sam Amick, joins Papa & Silver to reflect on Steph Curry's unprecedented journey to 4,000 three-pointers and how he overcame the ankle injuries that derailed the early stages of his career See omnystudio.com/listener for privacy information.

Senior NBA Writer for The Athletic, Sam Amick, joins Papa & Silver to reflect on Steph Curry's unprecedented journey to 4,000 three-pointers and how he overcame the ankle injuries that derailed the early stages of his career See omnystudio.com/listener for privacy information.

In this episode, Jonathan Pipek, founder and CEO of Blue Manta Consulting, joins Louise Liu to break down his method for crafting effective pricing and packaging strategies for early-stage startups. He shares key insights on identifying the right value metrics, avoiding common pricing pitfalls, and communicating pricing and packaging changes.For a step-by-step guide with editable template, please check out Jonathan Pipek's article: Pricing and Packaging Strategy for Early-stage Startups.All rights reserved. © Product Marketing Hive.

In this episode, I dive deep into the intricacies of tax season and how it's affecting business owners. We'll explore common questions around tax deductions, tax savings, and the strategies that are often suggested by various sources on the internet. While there are many legitimate strategies out there, I highlight the potential pitfalls and time costs related to overcomplicating your tax approach.   Through real-life anecdotes and practical advice, I urge you to reallocate your time towards activities that drive business growth, rather than spending countless hours on tax strategies that yield minimal returns. This episode encourages business owners to focus on building a profitable, high-value enterprise and to use simpler, effective tax practices that don't distract from the primary mission of growing their business. Tune in to understand how to balance tax savings with business productivity and set yourself up for long-term success.   What You'll hear in this episode: [0:50] Common Tax Questions During Tax Season [1:15] Overthinking Tax Deductions [2:00] Evaluating Tax Strategies [3:25] The Cost of Maintaining Tax Strategies [4:25] Focusing on Business Growth Over Tax Savings [5:55] When Tax Strategies Make Sense [7:55] The Importance of Developing Good Habits in The Early Stage of a Business   If you like this episode, check out: What Entrepreneurs Need to Know About Tax Deductions The Truth About Tax Savings and Strategies Is Hiring A Tax Strategist For You?   Want to learn more so you can earn more?  Visit keepwhatyouearn.com to dive deeper on our episodes  Visit keepwhatyouearncfo.com to work with Shannon and her team  Watch this episode and more here: https://www.youtube.com/channel/UCMlIuZsrllp1Uc_MlhriLvQ  Connect with Shannon on IG: https://www.instagram.com/shannonkweinstein/   The information contained in this podcast is intended for educational purposes only and is not individual tax advice. Please consult a qualified professional before implementing anything you learn.

Natalie explores why we feel so disappointed in early dating - is it the other person letting us down, or are we falling for our own fantasies? Learn to recognize when you're dating your imagination instead of the real person sitting across from you. Episode show notes: https://www.baggagereclaim.co.uk/289 Save 30% on Relationship Fundamentals classes: Readying for Love | Overcoming Dating Anxiety | The Compatibility Factor | Could This Be It? | Know Where You Stand | Co-Piloting Your Relationship Leave a voice note: https://www.speakpipe.com/baggagereclaim  Support the podcast and leave a tip: https://baggagereclaim.ck.page/products/podcast  'Reclaimed' membership: https://www.baggagereclaim.co.uk/reclaimed/ Work with me: https://www.baggagereclaim.co.uk/consultations/ Baggage Reclaim: https://www.baggagereclaim.co.uk  Shop courses and books: https://store.baggagereclaim.com Sign up for my newsletter: https://www.baggagereclaim.co.uk/newsletter/      

LikeFolio's Megan Brantley says Nvidia's (NVDA) web visits grew 22% year-over-year, showing consumer interest accelerating for the A.I. giant. She argues the company has room to switch gears in the event of volatility in the A.I. trade. Megan adds that the upside potential for Nvidia holds due to its reach in the industry.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Jamie Yuccas joins us from Los Angeles with insight on what the area looks like now weeks after wildfires destroyed so much of the area and the biggest problems LA faces in the early stages of recovery.

Today on the show we have Advith Chelikani, the Co-founder and CTO of Pylon.In this episode, Advith shares his journey from engineer to co-founder and how Pylon is redefining B2B customer support.We then discussed the role of product velocity in driving retention, the challenges of scaling customer success at an early-stage startup, and why founders should stay close to customers for as long as possible.We wrapped up by exploring the balance between growth and efficiency, the impact of AI in customer support, and the hiring strategies that have fueled Pylon's expansion.Mentioned ResourcesPylonChurn FM is sponsored by Vitally, the all-in-one Customer Success Platform.

In today's 40 Minute Mentor episode, we're joined by Dinika Mahtani, Partner at Cherry Ventures, the early-stage VC firm led by a team of entrepreneurs with experience building fast-scaling companies, such as Zalando and Spotify.  Prior to her move into VC, Dinika was an Operator, working across Banking, UberEats EMEA and Uber's JUMP e-bike product in the UK. She also served as Director of Finance and Operations at ClimateTech startup, Kaluza.  Today, we take a trip back down memory lane, discussing those fundamental years as an Operator and how she made the move into VC.  It's a conversation filled with mentorship for Founders and anyone considering the VC route as their next career step. 

How do early-stage founders break through and build exceptional companies? In this upcoming season of the I/O Podcast, hosts Sterling Snow and Tyler Hogge unveil a new approach—combining insights from the Exceptional Startups List with tactical advice from founders actively scaling their businesses. This season, we're setting out to be the best podcast in the world for seed and Series A founders.Episode Highlights:00:45 - The Big Change: Merging the Exceptional Startups List with the I/O PodcastWe're bringing on founders who are actively crossing key growth milestones—sharing real-time insights before they hit the mainstream.02:35 - Solving a Major Founder Challenge: Hiring Exceptional TalentThe Exceptional Startups List started as a resource for job seekers, but it's also helping founders attract top-tier talent.04:43 - Introducing I/O Podcast Snacks: High-Impact, Shorter EpisodesIn addition to our full-length episodes, we're launching I/O Snacks—quick, tactical interviews with startup leaders making waves.This season is all about delivering actionable, high-quality content tailored for founders navigating their early-stage journey. If you're looking for insights on scaling, hiring, and building a world-class startup, you won't want to miss this.Exceptional Startups List Here: https://exceptionalstartups.com/Follow the I/O Podcast Here: x: https://x.com/IO__podcastWeb: https://www.investoroperator.io/

Chris Hughen sat down with Erik Meira to discuss all things early stage ACL rehabilitation. We dive into a variety of topics including: swelling and calming the knee down, restoring range of motion, cyclops lesions, gait training, waking up the quads, and much more. Watch the full episode: https://youtu.be/eTFFS38be3k  Episode Resources: Prior Episodes with Erik: #31, #77, #116 Erik's Website: The Science PT PT Inquest Podcast --- Follow Us: YouTube: https://www.youtube.com/e3rehab  Instagram: https://www.instagram.com/e3rehab/ Twitter: https://twitter.com/E3Rehab --- Rehab & Performance Programs: https://store.e3rehab.com/  Newsletter: https://e3rehab.ck.page/19eae53ac1  Coaching & Consultations: https://e3rehab.com/coaching/  Mentoring: https://e3rehab.com/mentorship-intake-form/  Articles: https://e3rehab.com/articles/  --- Podcast Sponsors: Legion Athletics: Get 20% off using "E3REHAB" at checkout! - https://legionathletics.rfrl.co/wdp5g  Vivo Barefoot: Get 15% off all shoes! - https://www.vivobarefoot.com/e3rehab Tindeq: Get 10% off your dynamometer using code “E3REHAB” at checkout - https://tindeq.com/ --- @dr.surdykapt @tony.comella @dr.nicolept @chrishughen @nateh_24 --- This episode was produced by Kody Hughes

This episode discusses financial independence strategies, including Barista FI and Coast FI, along with insights into inherited accounts post-Secure Act (2020). Listeners will learn about health insurance considerations in early retirement, the dynamics of inherited IRAs, and how to manage finances during entrepreneurial transitions. The discussion highlights the importance of treating business expenses as valid investments and navigating inheritance with strategic planning. Timestamps & Key Takeaways: 00:01:28 Introduction to Barista FI and Coast FI Key Insight: Barista FI allows early withdrawals from retirement savings while supplementing income through part-time work. Takeaway: Understand the mechanics of Barista FI to reduce stress from job pressure when planning retirement. 00:04:13 Health Insurance Challenges in Early Retirement Key Insight: Health insurance costs can significantly impact your early retirement plans. Actionable Takeaway: Assess your health insurance situation and potential subsidies if considering early retirement. 00:19:08 Understanding Inherited Accounts Post-Secure Act Key Insight: The Secure Act requires non-spouse beneficiaries to deplete inherited retirement accounts within 10 years. Actionable Takeaway: Ensure all retirement accounts have updated beneficiary designations to avoid complications. 00:23:39 Simplifying Inherited IRA Management Key Insight: Spouses can assume the inherited IRA as their own, providing greater flexibility and simpler management. Takeaway: Review spouse beneficiary options when dealing with inherited accounts for optimal tax outcomes. 00:26:11 Using a Brokerage Account for Inheritance Advantages Key Insight: Brokerage accounts benefit from a step-up in basis, allowing heirs to sell securities with no capital gains tax immediately. Actionable Takeaway: Explore how to effectively utilize brokerage accounts for tax efficiency in inheritance. 00:45:58 Freedom from Inherited Advisors Key Insight: Remember, you are not obligated to keep the inherited advisor when managing inherited accounts. Takeaway: Take time to assess whether to maintain or change financial advisory relationships after inheriting accounts. 00:50:09 Investment Approaches in Early Stages of Entrepreneurship Key Insight: Treat your startup costs as investments in yourself and factor in the inherent risks. Action Item: Give yourself permission to direct resources into your business, rather than traditional savings during early entrepreneurship. Actionable Takeaways: Health Insurance Planning: Run the numbers for potential health insurance options based on your anticipated income when planning for early retirement. Beneficiary Check: Verify that all retirement accounts have up-to-date beneficiary designations to prevent issues for heirs. Business as an Investment: Reflect on viewing your business endeavors as valid investments, allowing you to adapt your financial strategy accordingly during entrepreneurial journeys. Quotes to Note: "Health insurance costs can significantly impact your early retirement plans." - Rachael Camp 00:04:13 "Spouses should ideally assume the inherited IRA as their own for simplicity." - Rachael Camp 00:23:39 "You don't have to inherit an advisor when you inherit accounts." - Rachael Camp 00:45:58 Related Resources: The Secure Act Detailed Explanation Health Insurance Subsidy Calculator Discussion Questions: How can understanding Barista FI change your approach to work and retirement? What strategies can help when dealing with inherited accounts? How does the Secure Act impact your financial planning for generational wealth?

In this episode, host Scott Becker sits down with Venkat Mocherla, Founder of Midstream Health, to discuss the evolving role of AI in healthcare, key trends in early-stage investing, and the transformative impact of AI-driven automation on clinicians, administrators, and patients.

The biggest mistakes made in the early stages of a relationship. How to tell if it's a BOT talking to you on social media. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What can I take for my recent early-stage glaucoma diagnosis?What supplements would be beneficial for immune deficiency?I'm 78 years old taking supplements and herbs for many years. Am I wasting my money?I recently fell and broke my wrist.  Should I be supplementing with calcium?

In this webinar turned podcast, Scott Becker speaks with Venkat Mocherla of Midstream AI. They discuss the latest developments in AI investment, the recent DeepSeek news and its impact on the market, how companies are adapting their strategies amidst shifting trends, and much more.

In the 24th “Wing and Tail Boys” podcast episode, Chris and Angelo discuss property management and food plotting with Mitchell Shirk, a row crop agronomist. They explore the complexities of agricultural practices, the shift towards regenerative farming, and the challenges faced by farmers in transitioning to no-till methods. The conversation also touches on public land management, the role of technology in agriculture, and the educational gaps that exist in understanding modern farming practices.  Throughout the conversation Chris, Angelo, and Mitchell discuss the complexities of modern farming practices, particularly focusing on the use of glyphosate, the importance of understanding soil health, and the challenges of no-till farming. They explore the historical context of land use, the knowledge gap between practitioners and researchers, and the strategies for effective planting and crop management.  The discussion emphasizes the need for a holistic approach to agriculture that considers both ecological balance and practical farming techniques. They go on to discuss the intricacies of soil temperature, planting timing, and the challenges of managing food plots in regions with shorter growing seasons. They explore strategies for effective food plot management, including the importance of diverse plant species and the impact of deer density on food plot success. The discussion also covers the implementation of no-till practices for new food plots and emphasizes the need to simplify complex agricultural practices for better understanding and execution. Learn more about your ad choices. Visit megaphone.fm/adchoices